Literature DB >> 19944069

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

Marie-Josée Massariol1, Songping Zhao, Martin Marquis, Diane Thibeault, Peter W White.   

Abstract

The bifunctional NS3 protease-helicase of hepatitis C virus (HCV), together with its cofactor protein NS4A, is an important target for antiviral drugs which can cure HCV infections. HCV strains are divided into six major genotypes based on sequence diversity, and the great majority of reports on NS3 have focused exclusively on genotype 1 proteins. Here we report the cloning, expression, and preliminary characterization of NS3-NS4A gene products from HCV genotypes 4, 5, and 6. This work complements our earlier characterization of genotype 2 and 3 proteins [17]. We compare NS3-NS4A protease and helicase activities of genotypes 4a, 5a, and 6a to those of common reference strains Con1 (genotype 1b) and JFH1 (genotype 2a). The specific activities of the proteases of the newly isolated proteins were similar to those of the reference proteins. Furthermore, the reference inhibitor BILN 2061 had similar activity against all of the proteins except for that of JFH1, which had an apparent K(i) that was 11-fold higher relative to Con1. RNA and DNA unwinding activities were also similar for genotypes 1, 4, 5, and 6 proteins, but significantly higher for genotype 2 JFH1. With the availability of these proteins, inhibitors developed based on their activity against genotype 1 can be tested against all the other major genotypes, providing a path to improved treatment for all HCV patients. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944069     DOI: 10.1016/j.bbrc.2009.11.122

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

Authors:  Lisette Lagacé; Peter W White; Christiane Bousquet; Nathalie Dansereau; Florence Dô; Montse Llinas-Brunet; Martin Marquis; Marie-Josée Massariol; Roger Maurice; Catherine Spickler; Diane Thibeault; Ibtissem Triki; Songping Zhao; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

2.  Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Authors:  Jeff A O'Meara; Christopher T Lemke; Cédrickx Godbout; George Kukolj; Lisette Lagacé; Benoît Moreau; Diane Thibeault; Peter W White; Montse Llinàs-Brunet
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

3.  Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

Authors:  Peter W White; Montse Llinàs-Brunet; Ma'an Amad; Richard C Bethell; Gordon Bolger; Michael G Cordingley; Jianmin Duan; Michel Garneau; Lisette Lagacé; Diane Thibeault; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

4.  Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

5.  Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.

Authors:  Abdo A Elfiky; Wael M Elshemey; Wissam A Gawad; Omar S Desoky
Journal:  Protein J       Date:  2013-01       Impact factor: 2.371

6.  A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity.

Authors:  Bradley Rimmert; Salwa Sabet; Edward Ackad; Mohammad S Yousef
Journal:  J Biomol Struct Dyn       Date:  2013-06-14

7.  1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease.

Authors:  Abdelsattar M Omar; Mahmoud A Elfaky; Stefan T Arold; Sameh H Soror; Maan T Khayat; Hani Z Asfour; Faida H Bamane; Moustafa E El-Araby
Journal:  Biomolecules       Date:  2020-03-21

8.  IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study.

Authors:  Abdo A Elfiky; Wael M Elshemey
Journal:  Med Chem Res       Date:  2016-03-04       Impact factor: 1.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.